Tonix Pharmaceuticals Expands TONMYA Coverage to 52 Million Commercial Lives

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a coverage agreement with a second major group purchasing organization, effective June 1, 2026, expanding access to TONMYA for an additional 17 million U.S. commercial lives. This brings total commercial coverage for the company’s fibromyalgia treatment to approximately 52 million lives, representing about 29% of the estimated 177 million commercially insured individuals in the United States.

The expansion marks a significant step in making TONMYA more widely available to patients suffering from fibromyalgia, a condition that affects an estimated 6-10 million people in the U.S. TONMYA, a non-opioid analgesic designed for daily bedtime administration and long-term use, was first launched commercially following an earlier coverage agreement announced in May that provided access to approximately 35 million commercial lives.

In addition to commercial coverage, TONMYA is now available through Medicaid programs covering approximately 75 million lives, while discussions with Medicare continue. This dual expansion into both commercial and government-sponsored insurance plans could substantially increase patient access to the first new treatment for fibromyalgia in more than 15 years.

The importance of this coverage expansion lies in the unmet medical need for fibromyalgia treatments. Fibromyalgia is characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties, and many existing treatments have limited efficacy or significant side effects. TONMYA offers a novel sublingual formulation of cyclobenzaprine, which is designed to provide rapid absorption and potentially fewer side effects compared to oral formulations.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is also evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, as well as advancing other pipeline candidates such as TNX-2900 for Prader-Willi syndrome and TNX-4800 for Lyme disease prophylaxis.

The coverage agreement underscores Tonix’s strategy to leverage group purchasing organizations to secure broad insurance coverage, a critical factor for the commercial success of any new drug. By covering 52 million commercial lives and 75 million Medicaid lives, TONMYA is positioned to reach a significant portion of the U.S. population. For investors, the expansion of coverage could translate into increased prescription volumes and revenue growth.

For more information on the latest news and updates relating to TNXP, visit the company’s newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/g826TT.

As Tonix continues to expand coverage and explore additional indications for TONMYA, the implications for patients and the broader fibromyalgia treatment landscape are substantial. The company’s progress in securing formulary access may serve as a model for other biotech firms seeking to launch innovative therapies in competitive markets.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Tonix Pharmaceuticals Expands TONMYA Coverage to 52 Million Commercial Lives.

The post Tonix Pharmaceuticals Expands TONMYA Coverage to 52 Million Commercial Lives appeared first on citybuzz.